Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 11 December 2025 - 18 December 2025

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

December 18, 2025 — Eli Lilly and Company (NYSE: LLY) is back in the spotlight after the drugmaker released new Phase 3 results for its experimental oral obesity medicine orforglipron, a development investors have been watching closely as the weight-loss market pushes beyond injections and into pills. At the same time, a report said Lilly is preparing material price cuts in Canada for its blockbuster medicines Mounjaro and Zepbound—a reminder that pricing and access remain central to the long-term investment case. Reuters+2Reuters+2 Eli Lilly stock price today LLY shares were trading around $1,060 on Thursday, December 18, up about 1.75%
18 December 2025
·····
Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly and Company (NYSE: LLY) stock traded in the mid-$1,050s in U.S. session Wednesday, December 17, 2025, hovering near recent highs as investors weighed fresh analyst commentary and new partnership headlines against an already-strong run for the pharma giant. In early trading, LLY was modestly higher, with the session range spanning roughly $1,051 to $1,064. The near-term story for Eli Lilly stock remains dominated by one theme: sustained demand for its GLP-1/“incretin” portfolio (Mounjaro and Zepbound today, and a growing next-generation pipeline for tomorrow). But the market is also increasingly focused on what comes next—especially the oral obesity candidate
17 December 2025
····
Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly and Company stock (NYSE: LLY) remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand. In early trading on Tuesday, Dec. 16, Eli Lilly shares hovered around the $1,050 area, after a year that included the company becoming the first drugmaker to reach a $1 trillion market value—a milestone that underscored how central Lilly’s metabolic franchise has become to investors.
16 December 2025
·····
Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025

Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025

Eli Lilly and Company (NYSE: LLY) ended Monday’s session (December 15, 2025) with a strong gain, and the stock was largely steady in after-hours trading—an important “temperature check” for investors heading into Tuesday’s open. As the market digests fresh headlines across obesity drugs, regulation, and litigation, Lilly remains one of the most closely watched names in healthcare—and one of the most influential stocks in major indexes. Here’s a detailed, news-driven look at what moved LLY today, what’s crossing the tape after the bell, and what matters most before the opening bell tomorrow. Eli Lilly stock price after the bell: where
15 December 2025
····
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company (NYSE: LLY) stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3 Below is what’s moving Eli Lilly stock as of 15.12.2025, what the latest forecasts imply, and which risks matter most heading into 2026. Eli Lilly stock price today: where LLY is trading on Dec. 15,
15 December 2025
·····
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Updated: December 14, 2025 Eli Lilly and Company (NYSE: LLY) heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating pricing pressure. The stock’s most recent close (U.S. markets were shut Sunday) was $1,027.51. StockAnalysis Over the past two weeks, Lilly headlines have clustered around three catalysts that matter directly to the stock: Below is a detailed, publication-ready roundup of the key news, forecasts, and analyst takes driving Eli Lilly stock as of 14.12.2025. What’s moving Eli Lilly stock right
14 December 2025
·····
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: (1) the obesity-drug arms race, (2) Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and (3) a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3 The result is a “defensive sector” that doesn’t feel defensive at all right now. The Federal Reserve’s Dec. 9–10 meeting delivered another layer
14 December 2025
········
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a steady stream of regulatory and access headlines that keep Lilly’s pipeline and pricing strategy in the spotlight. This week’s narrative was dominated by three themes investors will keep debating into the week ahead: (1) how big retatrutide can become—and whether
13 December 2025
····
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 (+1.80%) and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2 Note on timing: Saturday, Dec. 13, 2025 is a weekend, so U.S. stock markets
12 December 2025
·····
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY) is back in the spotlight on December 12, 2025, as the market digests a rapid sequence of obesity-pipeline headlines—alongside new questions about regulatory process, manufacturing scale-up, and what “priced for perfection” really means for one of healthcare’s most valuable companies. As of the latest quote available Friday, LLY traded around $1,009 per share, modestly higher on the day. Below is
12 December 2025
····
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day, after swinging between an intraday high above $1,030 and a low just under $990.Investing.com+1 Late in the session and into after‑hours trading, the stock hovered slightly above the close near $1,009, according to real‑time data. The move leaves LLY only
11 December 2025
·····
Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

The U.S. stock market is ending 2025 near record highs, but today’s tape is choppy: a fresh Federal Reserve rate cut is colliding with worries that AI spending is turning into a bubble.Reuters+1 Against that backdrop, investors are asking a familiar question: what are the best stocks to buy now in the U.S. market? Below is a news‑driven, research‑heavy look at eight U.S. stocks that many analysts and institutions see as compelling ideas to research in December 2025. Important: This article is for information and education only. It is not personalized financial advice. Always do your own research and consider
11 December 2025
··········
1 … 9 10 11 12 13

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop